JP3872509B2 - プロトンポンプ阻害剤含有獣医薬組成物 - Google Patents
プロトンポンプ阻害剤含有獣医薬組成物 Download PDFInfo
- Publication number
- JP3872509B2 JP3872509B2 JP52415994A JP52415994A JP3872509B2 JP 3872509 B2 JP3872509 B2 JP 3872509B2 JP 52415994 A JP52415994 A JP 52415994A JP 52415994 A JP52415994 A JP 52415994A JP 3872509 B2 JP3872509 B2 JP 3872509B2
- Authority
- JP
- Japan
- Prior art keywords
- proton pump
- pharmaceutical composition
- gel
- dry
- enteric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940126409 proton pump inhibitor Drugs 0.000 title claims abstract description 31
- 239000000612 proton pump inhibitor Substances 0.000 title claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 13
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 239000003349 gelling agent Substances 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 210000004211 gastric acid Anatomy 0.000 claims abstract description 8
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 239000011324 bead Substances 0.000 claims description 23
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- 229960000381 omeprazole Drugs 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000000576 coating method Methods 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000006174 pH buffer Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000011575 calcium Chemical class 0.000 claims description 5
- 239000002702 enteric coating Substances 0.000 claims description 5
- 238000009505 enteric coating Methods 0.000 claims description 5
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 5
- 239000011777 magnesium Chemical class 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 241000283086 Equidae Species 0.000 claims description 4
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 229960003174 lansoprazole Drugs 0.000 claims description 4
- 229960005019 pantoprazole Drugs 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 229910052782 aluminium Chemical class 0.000 claims description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- PSIREIZGKQBEEO-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylsulfinylmethyl)-n-methyl-n-(2-methylpropyl)aniline Chemical compound CC(C)CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 PSIREIZGKQBEEO-UHFFFAOYSA-N 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229950007395 leminoprazole Drugs 0.000 claims description 2
- 230000003139 buffering effect Effects 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 13
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 2
- 238000000034 method Methods 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 19
- 239000002245 particle Substances 0.000 description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000008188 pellet Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 241000283073 Equus caballus Species 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000230 xanthan gum Substances 0.000 description 6
- 229920001285 xanthan gum Polymers 0.000 description 6
- 235000010493 xanthan gum Nutrition 0.000 description 6
- 229940082509 xanthan gum Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229920000896 Ethulose Polymers 0.000 description 4
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 4
- 230000027119 gastric acid secretion Effects 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- -1 hydrogen ions Chemical class 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000011240 wet gel Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241001125840 Coryphaenidae Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241000283203 Otariidae Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241001423398 Ruscus hypoglossum Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE19939301489A SE9301489D0 (sv) | 1993-04-30 | 1993-04-30 | Veterinary composition |
| SE9301489-2 | 1993-04-30 | ||
| PCT/SE1994/000368 WO1994025070A1 (en) | 1993-04-30 | 1994-04-26 | Veterinary composition containing a proton pump inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH08509493A JPH08509493A (ja) | 1996-10-08 |
| JP3872509B2 true JP3872509B2 (ja) | 2007-01-24 |
Family
ID=20389791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52415994A Expired - Fee Related JP3872509B2 (ja) | 1993-04-30 | 1994-04-26 | プロトンポンプ阻害剤含有獣医薬組成物 |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US5731002A (is) |
| EP (1) | EP0696921B1 (is) |
| JP (1) | JP3872509B2 (is) |
| KR (1) | KR100324451B1 (is) |
| CN (1) | CN1100570C (is) |
| AT (1) | ATE199060T1 (is) |
| AU (1) | AU678830B2 (is) |
| BR (1) | BR9406363A (is) |
| CZ (1) | CZ285191B6 (is) |
| DE (1) | DE69426669T2 (is) |
| DK (1) | DK0696921T3 (is) |
| EE (1) | EE03137B1 (is) |
| EG (1) | EG20401A (is) |
| ES (1) | ES2155473T3 (is) |
| FI (1) | FI955124A0 (is) |
| GR (1) | GR3035831T3 (is) |
| HR (1) | HRP940267A2 (is) |
| HU (1) | HUT74868A (is) |
| IL (1) | IL109245A (is) |
| IS (1) | IS1694B (is) |
| LT (1) | LT3263B (is) |
| MA (1) | MA23170A1 (is) |
| NO (1) | NO312435B1 (is) |
| NZ (1) | NZ265728A (is) |
| PL (1) | PL176755B1 (is) |
| PT (1) | PT696921E (is) |
| RU (1) | RU2131267C1 (is) |
| SE (1) | SE9301489D0 (is) |
| SG (1) | SG52540A1 (is) |
| SK (1) | SK280465B6 (is) |
| TN (1) | TNSN94035A1 (is) |
| WO (1) | WO1994025070A1 (is) |
| YU (1) | YU22794A (is) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5708017A (en) * | 1995-04-04 | 1998-01-13 | Merck & Co., Inc. | Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6699885B2 (en) | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| AU773696B2 (en) * | 1998-10-06 | 2004-06-03 | Mars, Incorporated | Animal stereotypy |
| IL144131A0 (en) * | 1999-02-23 | 2002-05-23 | Merck & Co Inc | Pharmaceutical composition containing proton pump inhibitors |
| US6326384B1 (en) | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
| US6262085B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US6268385B1 (en) | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
| US6262086B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
| US6312723B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Pharmaceutical unit dosage form |
| US6312712B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
| US6780880B1 (en) | 1999-08-26 | 2004-08-24 | Robert R. Whittle | FT-Raman spectroscopic measurement |
| US6316020B1 (en) | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
| US6369087B1 (en) * | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| WO2002026210A2 (en) * | 2000-09-29 | 2002-04-04 | Geneva Pharmaceuticals Inc. | Proton pump inhibitor formulation |
| CN100528232C (zh) * | 2000-12-07 | 2009-08-19 | 尼科梅德有限责任公司 | 包含酸不稳定活性成分的混悬液形式的药物制剂 |
| DE10061135C1 (de) * | 2000-12-07 | 2002-11-07 | Byk Gulden Lomberg Chem Fab | Pharmazeutische Zubereitung in Form einer Paste enthaltend einen säurelabilen Wirkstoff |
| EP1341524B1 (en) | 2000-12-07 | 2011-10-19 | Nycomed GmbH | Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient |
| US20020192299A1 (en) * | 2000-12-28 | 2002-12-19 | Rajneesh Taneja | Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
| MXPA04007169A (es) * | 2002-01-25 | 2004-10-29 | Santarus Inc | Suministro transmucosal de inhibidores de bomba de protones. |
| CO5400144A1 (es) * | 2002-03-11 | 2004-05-31 | Novartis Ag | Compuestos organicos |
| US20030228363A1 (en) * | 2002-06-07 | 2003-12-11 | Patel Mahendra R. | Stabilized pharmaceutical compositons containing benzimidazole compounds |
| WO2004004690A1 (en) * | 2002-07-03 | 2004-01-15 | Abbott Laboratories | Liquid dosage forms of proton pump inhibitors |
| US20040006109A1 (en) * | 2002-07-03 | 2004-01-08 | Rajneesh Taneja | Liquid dosage forms of non-enterically coated acid-labile drugs |
| US20040005362A1 (en) * | 2002-07-03 | 2004-01-08 | Rajneesh Taneja | Liquid dosage forms of acid labile drugs |
| US20040082618A1 (en) * | 2002-07-03 | 2004-04-29 | Rajneesh Taneja | Liquid dosage forms of acid labile drugs |
| US20040081671A1 (en) * | 2002-07-03 | 2004-04-29 | Rajneesh Taneja | Liquid dosage forms of non-enterically coated acid-labile drugs |
| US20070243251A1 (en) * | 2002-12-20 | 2007-10-18 | Rajneesh Taneja | Dosage Forms Containing A PPI, NSAID, and Buffer |
| US20040121004A1 (en) * | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
| CA2517005A1 (en) * | 2003-02-20 | 2004-09-02 | Santarus, Inc. | A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| WO2005004921A1 (en) * | 2003-07-11 | 2005-01-20 | Astrazeneca Ab | Solid composition comprising a proton pump inhibitor |
| EP1648416A4 (en) * | 2003-07-18 | 2012-03-28 | Santarus Inc | PHARMACEUTICAL FORMULATIONS FOR INHIBITING THE ACIDIC ACIDIFICATION AND MANUFACTURING AND USE METHOD |
| JP2006528182A (ja) * | 2003-07-18 | 2006-12-14 | サンタラス インコーポレイティッド | 薬学的製剤および酸に起因する消化器疾患の治療法 |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| TWI372066B (en) * | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
| JP2007522217A (ja) * | 2004-02-10 | 2007-08-09 | サンタラス インコーポレイティッド | プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ |
| GB0403165D0 (en) * | 2004-02-12 | 2004-03-17 | Ct | Novel uses for proton pump inhibitors |
| US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US20060134210A1 (en) * | 2004-12-22 | 2006-06-22 | Astrazeneca Ab | Solid dosage form comprising proton pump inhibitor and suspension made thereof |
| JP2006176461A (ja) * | 2004-12-24 | 2006-07-06 | Dai Ichi Seiyaku Co Ltd | 粒状物 |
| EP1698233A1 (en) * | 2005-03-01 | 2006-09-06 | Bayer HealthCare AG | Reduction of digestibility of phosphorus in animal nutrition |
| US7981908B2 (en) | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
| US7803817B2 (en) | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
| EP2012756A4 (en) * | 2006-04-20 | 2013-01-23 | Inventia Healthcare Private Ltd | MULTI-UNIT COMPOSITIONS |
| CH698658B1 (de) * | 2006-04-24 | 2009-09-30 | Mepha Ag | Orale pharmazeutische Formulierung mit schneller Freisetzung für Pyridylmethylsulfinyl-Benzimidazole. |
| JP2009538901A (ja) * | 2006-06-01 | 2009-11-12 | デクセル ファーマ テクノロジーズ エルティーディー． | 複式ユニット製薬的製剤 |
| WO2008012621A2 (en) | 2006-07-25 | 2008-01-31 | Vecta, Ltd. | Compositions and meth0ds for inhibiting gastric acide secretion using derivatives of small dicarboxylic acids in combination with ppi |
| US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
| JP5319691B2 (ja) * | 2007-11-15 | 2013-10-16 | ノバルティス アーゲー | プラジカンテル、マクロライドラクトン、シクロデキストリンおよび粘稠化剤を含む駆虫ペースト |
| US20090227633A1 (en) * | 2008-03-04 | 2009-09-10 | Bassam Damaj | Methods to inhibit tumor cell growth by using proton pump inhibitors |
| EP2768488A4 (en) * | 2011-10-19 | 2015-04-15 | Rp Scherer Technologies Llc | TWO-PHASE PHARMACEUTICAL DELIVERY SYSTEM |
| US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| US20190151297A1 (en) * | 2016-04-29 | 2019-05-23 | Nauts Equine Brand Pty Ltd | Veterinary Composition |
| CN107468652A (zh) * | 2016-06-07 | 2017-12-15 | 北京新领先医药科技发展有限公司 | 一种固体干混悬温敏凝胶剂及其制备方法 |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| US10137111B2 (en) | 2016-08-11 | 2018-11-27 | Adamis Pharmaceuticals Corporation | Drug compositions comprising an anti-parasitic and proton pump inhibitor |
| US11564910B2 (en) | 2017-12-08 | 2023-01-31 | Adamis Pharmaceuticals Corporation | Drug compositions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL22368A (en) * | 1963-11-19 | 1969-01-29 | Merck & Co Inc | 2,5(or 6)-bis-heteroaryl substituted benzazoles |
| BE792990A (fr) * | 1971-12-23 | 1973-06-19 | Shell Int Research | Procede de lutte contre les endoparasites chez les chevaux |
| IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
| GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| US5215974A (en) * | 1986-11-21 | 1993-06-01 | Aktiebolaget Hassle | Certain pyridyl[(methylthio- or methyl sulfinyl)-2 benzimidazol-2-yl]N-methyl phosphonates useful for treating gastric-acid secretion related diseases |
| US5026560A (en) | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
| DK130287D0 (da) * | 1987-03-13 | 1987-03-13 | Benzon As Alfred | Oralt praeparat |
| YU48263B (sh) | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola |
| WO2011034149A1 (ja) | 2009-09-18 | 2011-03-24 | 旭硝子株式会社 | 二次電池用非水電解液 |
-
1993
- 1993-04-30 SE SE19939301489A patent/SE9301489D0/xx unknown
-
1994
- 1994-04-06 IS IS4146A patent/IS1694B/is unknown
- 1994-04-07 IL IL10924594A patent/IL109245A/xx not_active IP Right Cessation
- 1994-04-22 MA MA23476A patent/MA23170A1/fr unknown
- 1994-04-22 HR HR9301489-2A patent/HRP940267A2/hr not_active Application Discontinuation
- 1994-04-22 LT LTIP1920A patent/LT3263B/lt not_active IP Right Cessation
- 1994-04-26 PT PT94914665T patent/PT696921E/pt unknown
- 1994-04-26 AT AT94914665T patent/ATE199060T1/de not_active IP Right Cessation
- 1994-04-26 KR KR1019950704741A patent/KR100324451B1/ko not_active IP Right Cessation
- 1994-04-26 SK SK1354-95A patent/SK280465B6/sk unknown
- 1994-04-26 BR BR9406363A patent/BR9406363A/pt not_active Application Discontinuation
- 1994-04-26 AU AU66938/94A patent/AU678830B2/en not_active Ceased
- 1994-04-26 CN CN94191967A patent/CN1100570C/zh not_active Expired - Fee Related
- 1994-04-26 NZ NZ265728A patent/NZ265728A/en not_active IP Right Cessation
- 1994-04-26 DE DE69426669T patent/DE69426669T2/de not_active Expired - Fee Related
- 1994-04-26 JP JP52415994A patent/JP3872509B2/ja not_active Expired - Fee Related
- 1994-04-26 WO PCT/SE1994/000368 patent/WO1994025070A1/en active IP Right Grant
- 1994-04-26 EP EP94914665A patent/EP0696921B1/en not_active Expired - Lifetime
- 1994-04-26 ES ES94914665T patent/ES2155473T3/es not_active Expired - Lifetime
- 1994-04-26 CZ CZ952825A patent/CZ285191B6/cs not_active IP Right Cessation
- 1994-04-26 DK DK94914665T patent/DK0696921T3/da active
- 1994-04-26 HU HU9503085A patent/HUT74868A/hu unknown
- 1994-04-26 SG SG1996005767A patent/SG52540A1/en unknown
- 1994-04-26 PL PL94311276A patent/PL176755B1/pl unknown
- 1994-04-26 RU RU95122630/13A patent/RU2131267C1/ru active
- 1994-04-28 EG EG24594A patent/EG20401A/xx active
- 1994-04-28 TN TNTNSN94035A patent/TNSN94035A1/fr unknown
- 1994-04-29 US US08/235,258 patent/US5731002A/en not_active Expired - Lifetime
- 1994-11-17 EE EE9400377A patent/EE03137B1/xx unknown
-
1995
- 1995-04-27 YU YU22794A patent/YU22794A/sh unknown
- 1995-10-23 NO NO19954240A patent/NO312435B1/no unknown
- 1995-10-27 FI FI955124A patent/FI955124A0/fi not_active Application Discontinuation
-
2001
- 2001-05-07 GR GR20010400679T patent/GR3035831T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3872509B2 (ja) | プロトンポンプ阻害剤含有獣医薬組成物 | |
| JP4603631B2 (ja) | プロトンポンプ阻害剤を含有する医薬組成物 | |
| US6228400B1 (en) | Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same | |
| SK18252001A3 (sk) | Prípravok | |
| US8530500B2 (en) | Stable pharmaceutical omeprazole formulation for oral administration | |
| JP4513007B2 (ja) | 薬物吸収性改善剤 | |
| CA2347981C (en) | Process for the manufacturing of alkaline salts of substituted sulphinyl compounds and products prepared thereby | |
| EP1663173A1 (en) | Enteric soft gelatin capsule containing esomeprazole and method of preparation | |
| KR20020011990A (ko) | 위액에 불용인 마이크로그래뉼, 이의 제조방법 및 약제 | |
| CA2161683C (en) | Veterinary composition containing a proton pump inhibitor | |
| CA2392353A1 (en) | Stable acid labile benzimidazole pharmaceutical compositions | |
| TR201723199A2 (tr) | Yeni farmasötik bileşimler. | |
| CH697390B1 (de) | Orale pharmazeutische Formulierung für Pyridylmethylsulfinyl-Benzimidazole und Verfahren zu ihrer Herstellung. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040426 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040614 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040727 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060314 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060331 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060523 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060816 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20061010 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20061020 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |